remacemide has been researched along with Disease Models, Animal in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boehrer, A; Nehlig, A | 1 |
Bates, GP; Hockly, E | 1 |
Borchelt, DR; Chan, N; Coonfield, ML; Eaton, M; Fromholt, D; Gale, A; Morton, JL; Neslon, C; Ross, CA; Savonenko, AV; Schilling, G; Vorovich, E | 1 |
Borowicz, KK; Czuczwar, SJ; Luszczki, JJ; Malek, R; Patsalos, PN; Ratnaraj, N | 1 |
Borrelli, AR; Cregan, EF; Palmer, GC; Willett, F | 1 |
Anderson, DK; Farmer, JB; Lewis, AI; Upputuri, S; Zuccarello, M | 1 |
Andreassen, OA; Beal, MF; Dedeoglu, A; Ferrante, KL; Ferrante, RJ; Hersch, SM; Jenkins, BG | 1 |
2 review(s) available for remacemide and Disease Models, Animal
Article | Year |
---|---|
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Topics: Acetamides; Animals; Antioxidants; Creatine; Disease Models, Animal; Evaluation Studies as Topic; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Peptides; Point Mutation; Riluzole; Thioctic Acid; Trinucleotide Repeats; Ubiquinone | 2003 |
Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride.
Topics: Acetamides; Animals; Anticonvulsants; Brain; Cats; Cell Survival; Cerebrovascular Disorders; Disease Models, Animal; Humans; Hypoxia, Brain; Ischemic Attack, Transient; Mice; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Inbred SHR; Receptors, N-Methyl-D-Aspartate; S100 Calcium Binding Protein G; Subarachnoid Hemorrhage | 1995 |
5 other study(ies) available for remacemide and Disease Models, Animal
Article | Year |
---|---|
Effects of remacemide in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS.
Topics: Acetamides; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Male; Rats; Rats, Mutant Strains; Rats, Wistar; Seizures | 2003 |
Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Topics: Acetamides; Animals; Celecoxib; Chlorpromazine; Coenzymes; Cyclooxygenase Inhibitors; Disease Models, Animal; Disease Progression; Dopamine Antagonists; Environment, Controlled; Female; Humans; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Motor Skills; Neuroprotective Agents; Phenotype; Pyrazoles; Sulfonamides; Superoxide Dismutase; Superoxide Dismutase-1; Survival Rate; Treatment Outcome; Ubiquinone | 2004 |
Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock.
Topics: Acetamides; Algorithms; Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Interactions; Electroshock; Epilepsy; Epilepsy, Tonic-Clonic; Male; Memory; Mice; Motor Skills; Phenobarbital; Phenytoin; Seizures; Valproic Acid | 2007 |
Effect of remacemide hydrochloride on subarachnoid hemorrhage-induced vasospasm in rabbits.
Topics: Acetamides; Animals; Anticonvulsants; Cerebral Angiography; Cerebrovascular Circulation; Disease Models, Animal; Ischemic Attack, Transient; Male; Rabbits; Receptors, N-Methyl-D-Aspartate; Subarachnoid Hemorrhage | 1994 |
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Topics: Acetamides; Administration, Oral; Animals; Behavior, Animal; Body Weight; Brain; Cerebral Ventricles; Coenzymes; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Huntingtin Protein; Huntington Disease; Magnetic Resonance Imaging; Male; Mice; Mice, Transgenic; Motor Activity; Nerve Tissue Proteins; Nuclear Proteins; Organ Size; Survival Rate; Treatment Outcome; Ubiquinone | 2002 |